source
- Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trialIntellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
- Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…